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High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically
normal endometrium adjacent to endometrioid adenocarcinoma
Aims: To identify a DNA methylation signature of
endometrioid carcinoma of the endometrium (EEC) in
the early stages of endometrial carcinogenesis.
Methods and results: Archival biopsy specimens of
39 EECs, 14 cases of atypical hyperplasia (AH), 11
histologically normal endometrial tissues adjacent to
EECs and 24 normal control endometrial samples were
retrieved. The cases were tested by quantitative meth-
ylation-specific polymerase chain reaction with primers
hybridizing in the promoter regions of five genes
frequently methylated in human cancer (RASSF1A,
RARb2, P16, MGMT and GSTPi). Twenty-nine of 39
(74%) EECs and 7 ⁄ 14 (50%) AHs were methylated for
the RASSF1A gene, whereas 17 ⁄ 39 (44%) EECs and
6 ⁄ 14 (43%) AHs were positive for the methylation of
the RARb2 gene. No significant results were obtained
for the other genes (P16, MGMT and GSTPi). Interest-
ingly, 4 ⁄ 11 (36%) and 6 ⁄ 11 (55%) histologically
normal endometrial tissues adjacent to EEC showed,
respectively, RASSF1A and RARb2 gene methylation.
Furthermore, these 11 specimens were microsatellite
stable and showed similar proliferative, cell cycle and
apoptotic mean labelling indices as the normal endo-
metrial control tissues.
Conclusions: Promoter region methylation of RASSF1A
and RARb2 genes is an early event in endometrial
carcinogenesis.
Keywords: carcinoma, DNA methylation, endometrium, RARb2, RASSF1A
Abbreviations: AH, atypical hyperplasia; CpG, cytosine preceding directly a guanosine base; EEC, endometrioid
carcinoma of the endometrium; GSTPi, Pi-class glutathione S-transferase; LI, labelling index; MGMT,
O6-methylguanine DNA methyltransferase; MSH, microsatellite instability high; MSI, microsatellite instability;
MSS, microsatellite stable; PCR, polymerase chain reaction; RASSF1A, Ras-association domain gene family 1A;
RARb2, retinoic acid receptors beta 2; TMA, tissue microarray; TUNEL, terminal deoxynucleotidyl transferase
biotin-dUTP nick end labelling
Introduction
Endometrioid carcinoma of the endometrium (EEC)
accounts for about 80% of cases of endometrial
carcinoma, which is the most common gynaecological
malignancy in developed countries.1,2 Like most epi-
thelial malignancies, EEC results from the accumula-
tion of several abnormalities in oncogenes, tumour
suppressor genes and genes involved in DNA repair.
Once the tumour has developed, several additional
molecular alterations occur in different neoplastic
subclones. These new alterations are responsible for
tumour heterogeneity, tumour invasion and metasta-
sis.3 It has been acknowledged for more than 50 years
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that prolonged exposure to oestrogens in the absence of
sufficient levels of progestogens promotes the develop-
ment of atypical endometrial hyperplasia (AH) and,
subsequently, of EEC. AH is usually associated with
architecturally complex endometrial hyperplasia and
with an increased risk of evolution to EEC (25–40%).
This is in contrast to simple and complex hyperplasia
without atypia, which have a much lower risk of
malignant progression (1% and 3%, respectively).1,4
Typical risk factors for EEC are obesity, anovulatory
states, early menarche, late menopause, nulliparity and
unopposed exogenous oestrogens. These observations
have led to the development of an integrated model of
endometrial carcinogenesis involving both genetic and
hormonal mechanisms.2
In recent years, it has become clear that epigenetic
alterations are of importance in the regulation of gene
expression in diverse disease states, including neopla-
sia.5 DNA methylation is an epigenetic phenomenon
through which S-adenosyl-methionine (methyl donor)
adds a methyl group to the cytosine ring. This reaction
is catalysed by DNA methyl transferases and occurs in
the mammalian genome in nucleotide doublets, where
cytosine directly precedes a guanosine base (CpG
dinucleotide). Approximately half of the human gen-
ome has CpG islands on housekeeping genes and genes
with tissue-specific patterns of expression.6,7 DNA
methylation can modify the activity of these genes
without changing their sequences. Abnormal patterns
of DNA methylation have been recognized in various
cancers. In particular, increases in DNA methylation in
gene promoter regions are associated with silencing of
tumour suppressor genes and often precede apparent
malignant changes, suggesting that DNA methylation
assessment could be used for the early diagnosis of
cancer.5,7–10
DNA methylation status can be rapidly assessed by
methylation-specific polymerase chain reaction (PCR).
This method is based on the initial modification of DNA
by sodium bisulphite, converting all the unmethylated,
but not the methylated, cytosine to uracil and
subsequent amplification with primers specific for
methylated vs. unmethylated DNA. Moreover, this
technique facilitates the detection of a low number of
methylated alleles and is feasible on paraffin-embedded
material.11
Among the genes suspected of inducing human
cancers as a consequence of hypermethylation of their
promoter regions are RASSF1A, RARb2, P16, MGMT
and GSTPi. Alterations of these tumour suppressor
genes are frequently listed in various types of neo-
plasms.5 Ras-association domain gene family 1A
(RASSF1A) is a gene located at 3p21.3 region and
is known to induce cell cycle arrest through the
Rb-mediated checkpoint by inhibiting the accumula-
tion of cyclin D1.12,13 Retinoic acid receptor beta 2
(RARb2), present on chromosome 3p, has been found
to be silenced by methylation of the gene’s promoter
regions in a variety of human cancers, leading to
increased cellular proliferation, decreased differentia-
tion and apoptosis.14,15 P16INK4A is an inhibitor of the
cyclin D-dependent protein kinase 4 ⁄ 6, and its inacti-
vation leads to phosphorylation of retinoblastoma
protein and acceleration of the cell cycle.16 O6-Meth-
ylguanine DNA methyltransferase (MGMT) is a DNA
repair protein that removes mutagenic adducts from
the O6-guanine in DNA and hence protects against
mutations.17 Pi-class glutathione S-transferase (GSTPi)
acts as a tumour suppressor gene, as it codes for a
phase II metabolic enzyme that detoxifies reactive
electrophilic intermediates.18
The purpose of this study was to search for a




Paraffin-embedded tissue blocks of hysterectomy spec-
imens representing 39 EECs, 14 AHs and 11 of
histologically normal endometrium adjacent to EECs
were retrieved from patients aged 45–88 years. Also,
24 control endometrial tissue specimens from hyster-
ectomy specimens performed in women >50 years old
for benign non-endometrial pathology were taken.
The samples were obtained from the archives of the
Pathology Department of the University Hospital of
Liège. The protocol was approved by the Ethics
Committee of the University Hospital of Liège.
dna extraction
Before DNA extraction from the paraffin-embedded
tissue blocks, a 5 lm thick section was cut from each
tissue block and stained with haematoxylin and eosin
to confirm the histological diagnosis and to define
the purity of the normal or pathological tissue in the
blocks. DNA extraction was performed using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).
quantitative methylation-specif ic pcr
Sodium bisulphite treatment of genomic DNA was done
as described previously.11 Primers for detecting the
presence of methylated RASSF1A, RARb2, P16, MGMT
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and GSTPi genes, as well as the b-actin gene (chosen as
an internal control) are shown in Table 1.
Thermal cycling was performed by iCycler (BioRad,
Hercules, CA, USA) and initiated with an incubation
step of 5 min at 95C, followed by 47 cycles (95C for
30 s, 57C for 30 s, 72C for 30 s). The last step was
performed at 72C for 5 min. These conditions were
similar for RASSF1A, RARb2, P16, GSTPi and b-actin
genes, but different for MGMT gene (47 cycles; 95C for
30 s, 55C for 30 s, 72C for 30 s). The methylation
value was the ratio between the copy number of the
gene of interest ⁄ b-actin copy number · 1000. The
highest methylation value of the control endometrial
specimens from the non-cancerous patients was taken
as a cut-off, above which the cases were considered to
be hypermethylated.19
tissue microarray
The areas used for the construction of the tissue
microarrays (TMAs) were selected on the slides and on
the donor blocks and were sampled using a manual
arraying instrument (Beecher Instruments, Sun Prai-
rie, WI, USA). Two TMA blocks were constructed using
1-mm tissue cores (Alphelys, Plaisir, France). A total
of 88 spots represented the whole series (39 EECs, 14
AHs, 11 normal endometrial tissues adjacent to EEC
and 24 controls). The blocks were cut into 5-lm
sections and coated with paraffin for future use.
immunohistochemistry
Immunohistochemistry was carried out on the slides
obtained from the TMAs with anti-Ki67 (Dako, Glostrup,
Denmark) and anti-cyclin D1 (Novocastra, Newcastle,
UK) antibodies. The staining procedures were carried
out according to the manufacturers’ instructions. The
labelling index (LI) was calculated as the percentage
of immunopositive nuclei of endometrial epithelial or
tumour cells in 200–500 similar cells. The mean index
was then calculated for each of the two markers.
apoptosis assay
The terminal deoxynucleotidyl transferase biotin-dUTP
nick end labelling (TUNEL) assay for apoptosis was
performed using the In Situ Cell Death Detection Kit,
Alkaline Phosphatase (Roche, Indianapolis, IN, USA)
according to the manufacturer’s instructions. The
apoptotic cells and bodies were counted in all of the
endometrial epithelial or tumour cell populations in
each tissue core and the LI was calculated in the same
way as for immunohistochemistry.
microsatellite instabil ity
Five EECs, four AHs, five controls and the 11 normal
endometrial tissues adjacent to EEC as well as 11 other
normal paraffin blocks from the same patients (ovary,
cervix, appendix or tumour-free lymph nodes) were
further sectioned to assess microsatellite instability
(MSI). DNA extraction was done with the MagneSil
Genomic, Fixed Tissue System kit (Promega, Madison,
WI, USA). PCR was carried out to examine five mono-
nucleotide repeat markers (NR-21, BAT-26, BAT-25,
NR-24 and MONO-27) using the MSI Analysis System,
Version 1.1 (Promega). Fluorescence PCR sizing was
performed on a 3100 Genetic Analyzer (Applied Biosys-
tems, Foster City, CA, USA). For each tested sample, the
profile pattern of each repeat marker was compared with
its equivalent in normal tissue DNA. A shift in allele size
in the sample compared with a matched normal sample
was scored as MSI+ for this marker.20
statistical analysis
The methylation frequencies were analysed with the
two-tailed P-values calculated using Fisher’s exact test
(http://www.graphpad.com/quickcalcs/contingency1.
cfm). Differences in immunohistochemical mean LIs
were determined with unpaired t-test (http://www.
graphpad.com/quickcalcs/ttest1.cfm). P-values <0.05
were considered to be significant.
Table 1. Sequences of primers used for the detection of
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Results
quantitative methylation-specif ic pcr
After an initial run of five cases from each of the
diagnostic categories, valuable results were obtained
for two out of the five examined genes (RASSF1A and
RARb2). The different methylation values for each
diagnostic category are shown in Figure 1. Considering
the highest methylation value among the controls as
cut-off, EEC showed RASSF1A gene methylation in
29 ⁄ 39 (74%), whereas RARb2 gene methylation was
present in 17 ⁄ 39 (44%) of cases (Table 2). For the
different grades of EEC, RASSF1A and RARb2 gene
methylation was found, respectively, in 80 and 40% of
grade I, 67 and 33% of grade II and 75 and 58% of
grade III neoplasms. AH lesions showed RASSF1A and
RAR2b gene methylation in 7 ⁄ 14 (50%) and 6 ⁄ 14
(43%), respectively (Table 2). Of the 11 morphologi-
cally normal endometrial tissues adjacent to EEC, 4 ⁄ 11
(36%) showed methylation of the RASSF1A promoter
region and 6 ⁄ 11 (55%) RARb2 gene methylation
(Table 2). In each group of lesions, some were positive
for both markers and others for only one marker. The
combined sensitivities of the test in detecting one or
both genes together was higher in EECs and AHs, but
not in the normal endometrial tissues adjacent to EEC
(Table 2).
tissue microarray
The percentages of Ki67+ cells were very low in
normal endometrial tissues adjacent to EEC (1%), in
contrast to EEC (36%) and AH (13%). Similarly, the
mean LIs for cyclin D1 were <1% for normal endo-
metrial tissues adjacent to EEC compared with 14 and
8% for EEC and AH, respectively. The differences in the
mean LIs between EEC and AH were significant only for
Ki67 (P = 0.0074). As regards the apoptosis assay, the
means of LIs were low in all categories (<1%). For
the normal endometrial specimens (adjacent to EEC or
control), higher numbers of apoptotic cells and bodies
were observed in the specimens showing secretory
phase changes than in those with proliferative or
atrophic histology (data not shown).
microsatellite instabil ity
The five control samples, all 11 normal endometrial
tissues adjacent to EEC and the four AHs were
microsatellite stable (MSS). Two of the five tested EECs
(40%) showed high MSI (MSH) as assessed by the
detection of changes in repeat number in more than
one of the examined repeat markers. Representative
examples of MSH and MSS in EEC and adjacent normal































































































Figure 1. Scatterplot showing the methylation values in endo-
metrioid carcinoma of the endometrium (EEC) (rectangles), atypical
hyperplasia (diamonds), normal endometrial tissue adjacent to EEC
(circles) and control endometrial specimens (unshadowed rectangles)
for RASSF1A (A) and RARb2 genes (B). The horizontal lines represent
the mean values. The cut-off was determined by the highest value of
the control specimens from the non-cancerous patients.
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Discussion
As endometrial carcinogenesis is a multistep process
involving precursor lesions, the present study was
conducted to determine whether changes in methyla-
tion can be used for the early diagnosis of EEC. Like
other investigators,21,22 we found RASSF1A and
RARb2 gene methylation in a significant percentage
of EECs. Interestingly, in our study normal endometrial
tissues adjacent to EEC were also shown to have
frequent methylation in the RASSF1A and RARb2 gene
promoter region (36 and 55%, respectively), suggesting
the presence of multifocal epigenetic alterations during
endometrial carcinogenesis. The widely variable values
of CpG island methylation in this study suggest that
promoter region methylation is a markedly hetero-
geneous process. It is believed that the methylation
state is not always maintained and its extent at any
locus can change dramatically from one cell to another
and even from one CpG site to another.23,24 To explore
further the effect of epigenetic silencing of these two
genes, we examined proliferative activity (Ki67) and
cell cycle progression (cyclin D1) by immunohisto-
chemistry. It is known that RASSF1A gene induces cell
cycle arrest by inhibiting the accumulation of cyclin
D1. Furthermore, the induction of apoptosis may be
one of the effects of RASSF1A as a tumour suppressor
gene.25 Similarly, epigenetic silencing of RARb2 gene
expression may be sufficient to enhance malignant
transformation by modifying proliferation, differentia-
tion and apoptosis. This could occur without the need
for the mutated p53 gene.15 The lack of significant
increases in Ki67 and cyclin D1 protein expression in
normal endometrial tissues adjacent to EEC compared
with the controls may be related to the efficiency of
other unaffected mechanisms guarding against car-
cinogenesis. However, there were similar stepwise
increases of the mean immunohistochemical LIs
(Ki67 and cyclin D1) and methylation frequencies
(RASSF1A and RARb2) throughout the shift from
normal endometrium to AH and from AH to EEC. These
findings support the hypothesis that genetic alterations
accumulate along the transformation process ranging
from normal to premalignant and invasive patterns.
The TUNEL assay also failed to demonstrate a corre-
lation between methylation status and apoptotic indi-
ces in the 11 normal endometrial tissues adjacent to
EEC. In addition, these tissues were also MSS, indicat-
ing that RASSF1A and RARb2 gene methylation might
precede MSI in the initial stages of endometrial
carcinogenesis.
Tumour suppressor gene methylation changes in the
normal endometrium adjacent to EEC, even in the
absence of morphological or other molecular altera-
tions, might reflect a field cancerization process. This
hypothesis, proposed more than half of a century ago,
predicts that multiple cells form independent epithelial
tumours because carcinogenic exposure affects multi-
ple cells in the field. Another primary or synchronous
tumour may therefore arise from independent genetic
events. This concept originated from the observation
that a significant percentage of individuals with oral
cancer had multiple upper aerodigestive tract tumours
and from the finding of multiple invasive foci associated
with overlying areas of in situ squamous carcinoma.26
Although this hypothesis was first described for
tumours strongly related to carcinogenic factors such
as cigarette smoking, the view expanded over the next
five decades to cover tumours of other organs including
the female genital tract.27,28 Much attention has been
paid in recent years to the aberrant molecular (pre)
neoplastic changes occurring in the grossly normal
appearing tissue surrounding cancer. Although there is
a large body of literature reporting methylation fre-
quency in solid cancers, few studies have analysed
DNA methylation in normal and preneoplastic tissues
adjacent to tumours.8–10,12,15,29,30
Kanaya et al. observed frequent hypermethylation of
the MLH-1 gene promoter in normal endometrium
adjacent to endometrial carcinoma, supporting the
notion that hypermethylation of mismatch repair genes
is the initial step that triggers various genetic events,
namely MSI, in EEC carcinogenesis.31 As we have
demonstrated the presence of early RASSF1A and
Table 2. RASSF1A and RARb2 methylation frequencies in endometrioid carcinoma of the endometrium (EEC), atypical





RASSF1A and ⁄ or RARb2
methylation (%)
Endometrioid carcinoma of the endometrium 74 44 77
Atypical hyperplasia 50 43 64
Endometrium adjacent to endometrioid carcinoma 36 55 55
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RARb2 gene methylation in morphologically normal
endometrial cells without the appearance of MSI, our
results suggest that the DNA methylation process
starts in these two genes before it expands to involve
the MLH-1 gene promoter and subsequent evolution to
MSI.
In this study, the possible role of aberrant methyl-
ation in the progression of the disease has been
demonstrated by the higher methylation frequencies
with increasing severity of the lesion. On the other
hand, and more importantly, the occurrence of specific













Figure 2. Representative example of endometrioid carcinoma of the endometrium with methylation of RASSF1A and RARb2 genes (H&E) (A),
marked proliferative activity (Ki67 immunoperoxidase) (B), high cyclin D1 labelling index (immunoperoxidase) (C), scattered deeply eosinophilic
apoptotic cells and bodies (arrows) (TUNEL assay) (D) and high microsatellite instability pattern (arrows) (E).
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adjacent to EEC favours the role of methylation
imbalance in tumour initiation.23,32 Even if it is not
yet clear whether aberrant DNA methylation is a
result, a cause or both, of cancer development, our
study has demonstrated that promoter region methyl-
ation of RASSF1A and RARb2 genes may be among the
earliest events of endometrial carcinogenesis, as this












Figure 3. Representative example of normal endometrium adjacent to endometrioid carcinoma of the endometrium with methylation
of RASSF1A and RARb2 genes (H&E) (A), with no proliferative activity (Ki67 immunoperoxidase) (B), cyclin D1 immunonegativity
(immunoperoxidase) (C), deeply scattered eosinophilic apoptotic cells and bodies (arrows) (TUNEL assay) (D) and microsatellite stable pattern (E).
DNA methylation in endometrium near EEC 531
 2008 The Authors. Journal compilation  2008 Blackwell Publishing Ltd, Histopathology, 53, 525–532.
endometrial glandular cells before the appearance
of any discernible histopathological changes. These
data suggest that DNA methylation assessment may
be used for the early diagnosis of EEC. In addition,
as DNA methylation is a reversible process, novel
demethylating agents could help to treat or to
prevent EEC.
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